Drug Trial Radar · NCT01218789
Safety Study of Tasimelteon for Treatment of Non-24-Hour-Sleep-Wake Disorder in Blind Individuals With No Light Perception
Last checked: Nov 19, 2026Latest source record: Apr 3, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
140
Planned (sponsor's estimate)
Start
Oct 28, 2010
Primary completion
Dec 5, 2024
Study completion Dec 5, 2024
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Oct 11, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the safety of a one year open-label treatment of tasimelteon in male and female subjects with Non-24-Hour Sleep-Wake Disorder.
Conditions
- Non 24 Hour Sleep Wake Disorder
Interventions
tasimelteonDrug
20 mg tasimelteon capsules, PO daily for 1 year
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety EvaluationsTime frame: Week 4
- Safety EvaluationsTime frame: Week 8
- Safety EvaluationsTime frame: Week 12
- Safety EvaluationsTime frame: Week 16
- Safety EvaluationsTime frame: Week 26
- Safety EvaluationsTime frame: Week 34
- Safety EvaluationsTime frame: Week 42
- Safety EvaluationsTime frame: Week 52
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Garches, France
Site not named
Lille, France
Site not named
Lyon, France
Site not named
Montpellier, France
Site not named
Paris, France
Site not named
Rennes, France
Site not named
Toulouse, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.